Creative Medical Technology Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.6M
- Price
- $1.31
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.34%
- Volume
- 549.1K
About
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Quick stats
Shares outstanding6.6M
Computed float3.7M
Float / shares55.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001187953
AI Summary
AI-generated1/11
majorbullishclinical trial
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Creative Medical Technology Holdings announced the completion of enrollment and treatment across all cohorts of its ADAPT trial for CELZ-201 (Olastrocel), including an FDA-cleared opioid expansion cohort.
Interim data from the trial demonstrated statistically significant improvements in functional disability and pain reduction, with an independent Data Safety Monitoring Board confirming a favorable safety profile.
With the trial transitioning to follow-up, the company expects a meaningful decrease in clinical execution costs, which should extend its operating runway and support Phase 3 planning and RMAT evaluation without immediate fundraising.